Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report

JHOP - February 2022 Vol 12, No 1 - Case Reports, Tumor Lysis Syndrome, Breast Cancer
Blake T. Robbins, PharmD, MBA; Alexander M. Kreimer, PharmD, BCPS; Reema A. Patel, MD; Allison R. Butts, PharmD, BCOP
Dr Robbins is PGY2 Critical Care Pharmacy Practice Resident, and Dr Kreimer is Hematology Oncology Clinical Pharmacy Specialist, University of Kentucky HealthCare, Lexington, KY; Dr Patel is Assistant Professor of Medicine and Associate Program Director of Hematology/Oncology Fellowship, Markey Cancer Center, University of Kentucky, Lexington; Dr Butts is Oncology Clinical Coordinator and Program Director, PGY2 Hematology/Oncology Pharmacy Residency, University of Kentucky HealthCare, Lexington.
Download PDF

BACKGROUND: Tumor lysis syndrome (TLS) is a rare complication of breast cancer and is mostly described in case reports. Spontaneous TLS is even less common in patients who have not been exposed to antineoplastic treatment and may potentially be overlooked as a diagnosis. To our knowledge, 5 previous cases of spontaneous TLS in patients with breast cancer have been reported in the literature.

DISCUSSION: We present a 39-year-old patient with stage IV, HER2-positive ductal carcinoma, complicated by significant respiratory depression secondary to pleural effusions. Her hospital course was further complicated by worsening renal failure, initially thought to be of prerenal etiology, and later suspected to be spontaneous TLS. The patient was initiated treatment with rasburicase and hemodialysis, with subsequent improvement in renal function. Subsequently, she had a grade 4 hypersensitivity reaction to treatment with paclitaxel that might have been precipitated by a proinflammatory state related to spontaneous TLS.

CONCLUSION: This case further emphasizes that early identification and treatment of TLS are critical for the prevention of irreversible organ damage. Although rare, TLS should be considered in any patient with malignancy—hematologic or nonhematologic—who has acute renal failure, even if the patient has not yet received chemotherapy.

J Hematol Oncol Pharm.
2022;12(1):19-23
Disclosures at end of text

Tumor lysis syndrome (TLS) is characterized as a group of metabolic abnormalities caused by the release of intracellular contents that can lead to laboratory abnormalities of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Subsequent clinical abnormalities may manifest as renal impairment, cardiac arrhythmias, and seizures, which may be fatal. TLS is typically associated with rapidly growing malignancies, most often occurring in the setting of acute lymphoblastic leukemia or non-Hodgkin lymphoma.1

Nonhematologic malignancies are rarely associated with TLS, given their slower doubling time and response to therapy, but the case reports described in the literature include patients with breast cancer.2-4 TLS typically occurs within 1 day after the administration of cytotoxic chemotherapy, but it may also occur spontaneously.

Prompt recognition and treatment of TLS, including spontaneous TLS, are crucial for the prevention of serious complications, such as irreversible renal failure and death.1 Table 1 outlines the Cairo-Bishop diagnostic criteria for TLS.5,6

Table

Case Report

A 39-year-old woman with a history of hypertension presented to the University of Kentucky Medical Center as a transfer from an external hospital with worsening shortness of breath. The patient had multiple previous clinic and emergency department visits for unexplained shortness of breath, with little improvement from an outpatient course of treatment with doxycycline. At the outside hospital, she initiated treatment with a nebulizer and steroids (Table 2).

Table

A diagnostic mammogram performed 2 weeks before the described admission revealed a 4.2-cm × 3.6-cm irregular mass of the right breast, with ultrasound-guided core biopsy showing poorly differentiated invasive ductal carcinoma that was negative for estrogen receptor, weakly (<5%) positive for progesterone receptor, and was HER2-positive by fluorescence in situ hybridization. A chest x-ray showed bilateral pleural effusions.

Laboratory test results from the external hospital 24 hours before transfer showed sodium levels of 141 mmol/L; chloride, 107 mmol/L; blood urea nitrogen, 7 mg/dL; potassium, 3.8 mmol/L; carbon dioxide, 27 mmol/L; and serum creatinine, 0.75 mg/dL.

Computed tomography (CT) of the chest with contrast was negative for pulmonary embolism, but detected metastatic nodules in the right lung and pleural surfaces, bulky mediastinal adenopathy, and a left lower lobe consolidation (Figure 1).

Figure

The patient was treated for pneumonia with ceftriaxone and azithromycin and underwent a left-sided thoracentesis, and 1.5 liters of fluid were removed. Given the worsening respiratory status, she was transferred to our academic medical center for further workup.

On arrival, the patient’s serum creatinine had elevated to 2.09 mg/dL. Her differential diagnoses included prerenal acute kidney injury from the thoracentesis fluid removal or contrast-induced nephropathy from her previous CT. An echocardiogram was performed and was unremarkable.

The patient was placed on broad-spectrum antibiotics and was admitted to the medical intensive care unit (ICU). On hospital day 3, she underwent a left-sided thoracentesis, and another 1.5 liters of fluid were removed with pleural cytology and cultures were unremarkable. Left- and right-sided pleural drains were placed on hospital days 5 and 6.

The patient’s hospital course was further complicated by worsening renal failure, with creatinine and phosphorus steadily trending up, peaking at 8.93 mg/dL and 10.3 mg/dL, respectively, and a concurrent unadjusted serum calcium nadir to 7.6 mg/dL on day 11. A fractional excretion of sodium of 0.7% was consistent with a prerenal etiology. However, the patient was unresponsive to fluid throughout the hospitalization.

On hospital day 9, her uric acid level was 15.5 mg/dL. The patient received 1 dose of rasburicase 3 mg and was initiated treatment with allopurinol for possible TLS. Although she had been receiving fluids throughout her admission, subsequent hydration was held because of recurrent pleural effusions. She was subsequently started with intermittent hemodialysis because of her persistent electrolyte abnormalities after the administration of rasburicase, which collectively led to downtrending of her creatinine and uric acid levels (Figure 2).

Figure

Because the patient was clinically improving, the medical oncology service consented for the patient to receive weekly paclitaxel administration while she was an inpatient, beginning on hospital day 13, with plans to add anti-HER2 therapy at hospital discharge. Before the administration of chemotherapy, the patient was medically stable, apart from persistent nausea and vomiting, for which she received scheduled treatment with olanzapine and scopolamine, and as-needed treatment with prochlorperazine, ondansetron, and lorazepam in the 24 hours preceding administration of chemotherapy.

She was premedicated with dexamethasone, cetirizine, and famotidine, and then started treatment with paclitaxel 80 mg/m2. Approximately 20 minutes into her infusion, she had a grade 4 hypersensitivity reaction, which subsequently progressed to a cardiopulmonary arrest. Her infusion was immediately stopped, and she received diphenhydramine, famotidine, hydrocortisone, and epinephrine.

The return of spontaneous circulation was achieved after 1 round of advanced cardiac life support. She required intubation for airway protection and was transferred to the medical ICU. Of note, her corrected QT (QTc) interval before cardiopulmonary arrest was 537 milliseconds (which was not explicitly identified as torsades).

The patient remained stable on hospital day 14 and was extubated. No further chemotherapy was administered while she was in the hospital, and follow-up within an outpatient clinic was coordinated. She continued to require intermittent hemodialysis and was discharged on hospital day 22, with a plan to continue thrice weekly hemodialysis.

Table 3 describes the patient’s laboratory values during her 22-day hospitalization. The pleural drain remained in place, with intermittent drainage at home. The patient returned for trastuzumab administration and was monitored in the hospital overnight, with no reaction reported. Although she no longer required hemodialysis, her kidney function was classified as chronic kidney disease class 3.

Table

Discussion

Mortality resulting from TLS in patients with solid tumors is significantly higher than in patients with hematologic malignancies (39% vs 1.9%, respectively), and is mostly attributed to acute kidney injury.7 One hypothesis for this difference in mortality rate is that in patients with a solid tumor, TLS more often occurs in the presence of a large tumor burden, which is also associated with increased mortality.7

Spontaneous TLS occurs even less often in patients who have not been exposed to antineoplastic treatment. A retrospective systematic review evaluating published cases of TLS from 1960 to 2017 identified 132 patients with TLS in solid tumor, with 76% of them associated with the treatment regimens, and 24% of them occurring spontaneously.8

To our knowledge, 5 case reports of spontaneous TLS in breast cancer were previously published.5,9-12 All of these cases were associated with significant tumor burden, and with metastasis to the liver in 4 of the 5 cases,5,9,11,12 conditions that are associated with spontaneous TLS.8

The Cairo-Bishop definition of TLS is often used for a definitive diagnosis of clinical TLS, which requires at least 2 laboratory abnormalities and 1 clinical manifestation, as noted in Table 1.5,6 Our patient met the criteria for laboratory TLS, with uric acid of >8 mg/dL and phosphorus of >4.5 mg/dL. The criteria for clinical TLS were also present in our patient, with acute kidney injury and potential cardiac dysrhythmia.

The treatment for TLS requires aggressive hydration; electrolyte management; antihyperuricemic agents, including allopurinol and rasburicase; and dialysis in patients with refractory disease.13 Rasburicase is a recombinant-urate-oxidase enzyme used to convert uric acid into an inactive metabolite that works rapidly to metabolize circulating uric acid.13 Conversely, allopurinol, a xanthine oxidase inhibitor, reduces further formation of uric acid via purine catabolism but does not directly reduce uric acid already in circulation.13

The preferred treatment of stage IV, HER2-positive breast cancer is docetaxel or paclitaxel plus pertuzumab and trastuzumab.14 Docetaxel or paclitaxel may be used in patients receiving hemodialysis because these agents are nondialyzable.15 Paclitaxel is administered in a solution of ethanol and polyoxyl 35 castor oil, which is known to cause hypersensitivity reactions.16 In patients receiving paclitaxel, minor hypersensitivity reactions occurred in 40% of patients, whereas severe reactions occur in 1.3%.17

A number of confounding factors and the rarity of TLS in solid tumor led to a delay in the workup of TLS in our patient. The patient’s acute kidney injury was attributed to prerenal disease or to acute tubular necrosis, and further workup for TLS was overlooked. The patient’s potentially nephrotoxic medications used during hospitalization are outlined in Table 4.

Table

Her cardiac arrythmia might have been multifactorial—from a potential hypersensitivity reaction, prolonged QTc interval secondary to polypharmacy, and electrolyte abnormalities. Because our patient’s potassium level was normal throughout the hospitalization, cardiac arrythmia was more likely related to paclitaxel hypersensitivity. Although our patient received appropriate premedications to reduce the risk for hypersensitivity reaction, her risk for paclitaxel hypersensitivity might have been increased, because of the underlying TLS. Aside from electrolyte abnormalities, tumor lysis releases intracellular cytokines (tumor necrosis factor–alpha, interleukin [IL]-6, IL-10) which can precipitate a proinflammatory state, potentially inducing an anaphylactoid hypersensitivity reaction.7

Conclusion

Our patient presents a rare case of spontaneous TLS in a woman with stage IV, HER2-positive breast cancer. Her diagnosis of TLS was confounded by significant respiratory depression secondary to pleural effusions, the administration of contrast, and the rarity of spontaneous TLS in patients with breast cancer. This case further emphasizes that the early identification and treatment of TLS are critical for the prevention of irreversible organ damage and death. Although rare, TLS should be considered in any patient with hematologic or nonhematologic malignancy who has acute renal failure, even before the administration of chemotherapy.

Author Disclosure Statement
Dr Robbins, Dr Kreimer, Dr Butts, and Dr Patel have no conflicts of interest to report.

References

  1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854. Erratum in: N Engl J Med. 2018;379:1094.
  2. Taira F, Horimoto Y, Saito M. Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature. Breast Cancer. 2015;22:664-668.
  3. Carrier X, Gaur S, Philipovskiy A. Tumor lysis syndrome after a single dose of atezolizumab with nab-paclitaxel: a case report and review of literature. Am J Case Rep. 2020;21:e925248. doi: 10.12659/AJCR.925248.
  4. Vaidya GN, Acevedo R. Tumor lysis syndrome in metastatic breast cancer after a single dose of paclitaxel. Am J Emerg Med. 2015;33:308.e1-308.e2.
  5. Parsi M, Rai M, Clay C. You can’t always blame the chemo: a rare case of spontaneous tumor lysis syndrome in a patient with invasive ductal cell carcinoma of the breast. Cureus. 2019;11:e6186. doi: 10.7759/cureus.6186.
  6. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.
  7. Findakly D, Luther RD III, Wang J. Tumor lysis syndrome in solid tumors: a comprehensive literature review, new insights, and novel strategies to improve outcomes. Cureus. 2020;12:e8355. doi: 10.7759/cureus.8355.
  8. Harmon J, Allen S, Stoyanova D, et al. The clinical features, outcome and prognosis of spontaneous tumor lysis syndrome in solid tumor. J Oncol Res Forecast. 2018;1:1009.
  9. Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 1995;18:71-73.
  10. Goyal H, Sawhney H, Singh J. Spontaneous fatal recurrent tumor lysis syndrome in ductal breast carcinoma. Community Oncol. 2012;9:136-137.
  11. Elfar A, Teleb M, Rodriguez-Castro CE, Nahleh Z. Spontaneous tumor lysis syndrome in breast cancer: a case report and discussion. J Cancer Ther Res. 2013;2:9. doi: 10.7243/2049-7962-2-9.
  12. Cordrey EO, Dienhart JA, Wang J. Spontaneous tumor lysis syndrome in a giant neglected breast cancer. J Mol Oncol Res. 2018;2:38-41.
  13. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-2778. Erratum in: J Clin Oncol. 2010;28:708.
  14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer. Version 2.2022. December 20, 2021. www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 31, 2022.
  15. Leung TV, Hughes ME, Cambareri CG, et al. Systemic treatments for lung cancer patients receiving hemodialysis. J Adv Pract Oncol. 2018;9:614-629.
  16. Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol. 2014;21:e630-e641.
  17. Syrigou E, Triantafyllou O, Makrilia N, et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. Inflamm Allergy Drug Targets. 2010;9:206-213.
Related Items
Managing Resistant Fusarium Infections in Immunocompromised Pediatric Patients with Malignancy: 2 Case Reports and Review of the Literature
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Case Reports
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer
New Formulation of Bendamustine Associated with Phlebitis: Report of 2 Unique Patient Cases
Veronica Ajewole, PharmD, BCOP, Lindsay Edmondson, PharmD, BCOP, Edward McLean, PharmD, BCOP, Kirk Heyne, MD, Lawrence Rice, MD
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in Case Reports
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice published on February 3, 2022 in Clinical Trials, Breast Cancer
2021 Breast Cancer Year in Review Introduction
2021 Year in Review - Breast Cancer published on January 21, 2022 in Breast Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.